WallStSmart

Clearpoint Neuro Inc (CLPT)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 62120% more annual revenue ($25.27B vs $40.61M). SYK leads profitability with a 13.2% profit margin vs -71.6%. CLPT appears more attractively valued with a PEG of 0.61. SYK earns a higher WallStSmart Score of 59/100 (C).

CLPT

Hold

37

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.3Quality: 5.0
Piotroski: 4/9Altman Z: -2.65

SYK

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CLPTUndervalued (+10.6%)

Margin of Safety

+10.6%

Fair Value

$14.96

Current Price

$12.89

$2.07 discount

UndervaluedFair: $14.96Overvalued
SYKSignificantly Overvalued (-35.2%)

Margin of Safety

-35.2%

Fair Value

$223.02

Current Price

$305.66

$82.64 premium

UndervaluedFair: $223.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLPT2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
42.9%10/10

Revenue surging 42.9% year-over-year

PEG RatioValuation
0.618/10

Growing faster than its price suggests

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.44B9/10

Large-cap with strong market position

Areas to Watch

CLPT4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$429.45M3/10

Smaller company, higher risk/reward

Price/BookValuation
20.5x2/10

Trading at 20.5x book value

Return on EquityProfitability
-154.3%2/10

ROE of -154.3% — below average capital efficiency

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
33.9x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CLPT

The strongest argument for CLPT centers on Revenue Growth, PEG Ratio. Revenue growth of 42.9% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bear Case : CLPT

The primary concerns for CLPT are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 3.37 is elevated, increasing financial risk.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

CLPT profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.

CLPT carries more volatility with a beta of 1.31 — expect wider price swings.

CLPT is growing revenue faster at 42.9% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Bottom Line

SYK scores higher overall (59/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Clearpoint Neuro Inc

HEALTHCARE · MEDICAL DEVICES · USA

ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.

Visit Website →

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?